NasdaqGM - Nasdaq Real Time Price • USD
MannKind Corporation (MNKD)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | 0.03 | 0.03 | 0.13 | 0.25 |
Low Estimate | 0.01 | 0.01 | 0.06 | 0.14 |
High Estimate | 0.04 | 0.06 | 0.26 | 0.36 |
Year Ago EPS | -0.04 | -0.02 | -0.04 | 0.13 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | 60.49M | 63.72M | 259.92M | 319.91M |
Low Estimate | 56.6M | 59.5M | 241.5M | 280.13M |
High Estimate | 66.71M | 74.46M | 308.53M | 368.82M |
Year Ago Sales | -- | 48.61M | 198.96M | 259.92M |
Sales Growth (year/est) | -- | 31.10% | 30.60% | 23.10% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.05 | -0.04 | -0.02 | 0 |
EPS Actual | -0.04 | -0.02 | 0.01 | 0 |
Difference | 0.01 | 0.02 | 0.03 | 0 |
Surprise % | 20.00% | 50.00% | 150.00% | -- |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.03 | 0.03 | 0.13 | 0.25 |
7 Days Ago | 0.03 | 0.03 | 0.13 | 0.25 |
30 Days Ago | 0.03 | 0.03 | 0.1 | 0.25 |
60 Days Ago | 0.01 | 0.02 | 0.09 | 0.22 |
90 Days Ago | 0.01 | 0.01 | 0.09 | 0.22 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | MNKD | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 175.00% | -- | -- | 0.40% |
Next Qtr. | 250.00% | -- | -- | 9.90% |
Current Year | 425.00% | -- | -- | 4.30% |
Next Year | 92.30% | -- | -- | 13.40% |
Next 5 Years (per annum) | 35.60% | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/15/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/28/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 1/4/2024 |
Initiated | Wedbush: Outperform | 10/10/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/8/2023 |
Related Tickers
UTHR United Therapeutics Corporation
234.47
+0.18%
LQDA Liquidia Corporation
12.95
-1.75%
GERN Geron Corporation
3.5000
-6.17%
RXRX Recursion Pharmaceuticals, Inc.
7.70
+1.32%
AKBA Akebia Therapeutics, Inc.
1.3700
+0.74%
SGMO Sangamo Therapeutics, Inc.
0.5209
+2.12%
AVXL Anavex Life Sciences Corp.
3.6800
0.00%
LPTX Leap Therapeutics, Inc.
3.2000
-0.31%
NRXP NRx Pharmaceuticals, Inc.
3.0500
+1.67%
LCTX Lineage Cell Therapeutics, Inc.
1.1400
0.00%